| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross margin | 55,3 k € | -99.7% | 18,1 M € | +208.6% | -16,6 M € | +29.9% | -23,7 M € | -57.5% | -15,1 M € | -105.2% | -7,3 M € | -22.4% | -6,0 M € | -70.5% | -3,5 M € | +1.9% | -3,6 M € | -8.0% | -3,3 M € | -40.8% | -2,4 M € | +6.3% | -2,5 M € | -101.0% | -1,3 M € | -133.4% | -536,9 k € | |
| EBITDA | -500,0 k € | -102.8% | 17,7 M € | +176.1% | -23,3 M € | +21.8% | -29,8 M € | -56.0% | -19,1 M € | -84.2% | -10,4 M € | -19.3% | -8,7 M € | -42.4% | -6,1 M € | +1.3% | -6,2 M € | -10.5% | -5,6 M € | -35.9% | -4,1 M € | -25.2% | -3,3 M € | -101.4% | -1,6 M € | -204.4% | -537,2 k € | |
| Operating profit | -500,0 k € | -102.9% | 17,0 M € | +171.9% | -23,6 M € | +21.5% | -30,1 M € | -54.7% | -19,5 M € | -80.6% | -10,8 M € | -18.2% | -9,1 M € | -39.7% | -6,5 M € | +2.3% | -6,7 M € | -10.5% | -6,0 M € | -35.3% | -4,5 M € | -26.5% | -3,5 M € | -106.2% | -1,7 M € | -211.4% | -549,8 k € | |
| Profit/loss | -519,5 k € | -103.1% | 16,5 M € | +133.8% | -49,0 M € | -61.8% | -30,3 M € | -45.8% | -20,8 M € | -70.1% | -12,2 M € | -32.6% | -9,2 M € | -37.0% | -6,7 M € | -0.5% | -6,7 M € | -10.6% | -6,0 M € | -35.4% | -4,5 M € | -27.3% | -3,5 M € | -107.0% | -1,7 M € | -207.5% | -551,3 k € | |
| Equity | -1,5 M € | -53.2% | -976,5 k € | +94.4% | -17,5 M € | -155.8% | 31,4 M € | +35.7% | 23,2 M € | +1486.3% | -1,7 M € | -116.0% | 10,4 M € | +16.2% | 9,0 M € | +64.1% | 5,5 M € | -10.9% | 6,1 M € | +46.2% | 4,2 M € | +1196.1% | -382,9 k € | -112.3% | 3,1 M € | +67.6% | 1,9 M € | |
| Total assets | 4,3 M € | -1.7% | 4,4 M € | -43.2% | 7,8 M € | -84.1% | 48,7 M € | +15.6% | 42,1 M € | +93.6% | 21,8 M € | -15.7% | 25,8 M € | +75.8% | 14,7 M € | +16.4% | 12,6 M € | +7.1% | 11,8 M € | +48.3% | 7,9 M € | +50.8% | 5,3 M € | -11.7% | 6,0 M € | +185.5% | 2,1 M € | |
| Cash | 611,0 € | -78.4% | 2,8 k € | -99.9% | 2,3 M € | -78.0% | 10,4 M € | -13.4% | 12,1 M € | +228.3% | 3,7 M € | -65.6% | 10,7 M € | +2.0% | 10,5 M € | +34.9% | 7,8 M € | +64.7% | 4,7 M € | +509.7% | 773,9 k € | +33.5% | 579,6 k € | -80.6% | 3,0 M € | +1031.5% | 264,1 k € | |
| Debts | 5,8 M € | +8.2% | 5,4 M € | -78.1% | 24,6 M € | +47.8% | 16,7 M € | -10.2% | 18,5 M € | -20.8% | 23,4 M € | +54.3% | 15,2 M € | +176.4% | 5,5 M € | -10.5% | 6,1 M € | +33.7% | 4,6 M € | +49.0% | 3,1 M € | -29.4% | 4,4 M € | +75.3% | 2,5 M € | +975.9% | 231,5 k € | |
| Staff | — | 6,1 | 78,9 | 69,5 | 46,2 | 38,3 | 36 | 36,2 | 39,2 | 37,6 | 36,5 | 16 | 6 | — | ||||||||||||||
Public limited company · Mont-Saint-Guibert · incorporated on 12/02/2009
Company — Opening of bankruptcy.
Public limited company loss-making in the latest fiscal year. Cash position declining (-78.4%).
Acceptable counterparty for a moderate engagement. Require 2 fiscal years of detailed accounts before any significant exposure. The abridged model hides revenue.
PROMETHERA BIOSCIENCES is a Public limited company incorporated in 2009. Its main activity is: Other human health activities. Its registered office is in Mont-Saint-Guibert.
Key indicators
7-day free trial, no credit card required.
7-day free trial, no credit card required.
7-day free trial, no credit card required.
Source: Belgian Official Gazette